Dimensional Fund Advisors LP Increases Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Dimensional Fund Advisors LP increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 18.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,387,862 shares of the medical research company's stock after buying an additional 214,046 shares during the quarter. Dimensional Fund Advisors LP owned about 0.76% of IQVIA worth $272,744,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. World Investment Advisors LLC purchased a new stake in IQVIA during the 3rd quarter valued at approximately $14,633,000. Arvest Bank Trust Division acquired a new stake in shares of IQVIA in the 3rd quarter worth $21,079,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of IQVIA in the third quarter valued at about $2,310,000. Tidal Investments LLC increased its stake in shares of IQVIA by 9.3% during the third quarter. Tidal Investments LLC now owns 5,980 shares of the medical research company's stock worth $1,417,000 after acquiring an additional 509 shares during the period. Finally, Franklin Resources Inc. raised its holdings in IQVIA by 1.2% during the third quarter. Franklin Resources Inc. now owns 501,807 shares of the medical research company's stock worth $117,031,000 after purchasing an additional 6,011 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Robert W. Baird dropped their target price on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 21st. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. Truist Financial decreased their target price on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. UBS Group cut their price target on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a report on Friday, February 7th. Finally, Barclays reissued an "equal weight" rating and set a $170.00 price objective (down previously from $235.00) on shares of IQVIA in a report on Thursday, April 10th. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $241.50.

IQVIA Trading Up 2.5 %

Shares of NYSE IQV traded up $3.64 during midday trading on Thursday, reaching $150.70. 1,457,557 shares of the stock were exchanged, compared to its average volume of 1,419,443. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market capitalization of $26.57 billion, a P/E ratio of 20.09, a P/E/G ratio of 1.99 and a beta of 1.46. The stock has a 50 day moving average price of $173.32 and a 200-day moving average price of $195.09. IQVIA Holdings Inc. has a 52-week low of $135.97 and a 52-week high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.